Therapy Areas: Inflammatory Diseases
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
2 October 2026 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and ado...
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
2 October 2026 - Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new pu...
AFYREN ingredient enables global launch of natural propionic acid skincare product
1 October 2026 - Greentech company AFYREN (Euronext Paris:ALAFY) said on Thursday that it its 100% bio-based, COSMOS-certified propionic acid has enabled the global launch of Esse Barrier Rescue, deve...
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
30 September 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive Phase 2b results for tulisokibart, an investigation...
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its N...
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
29 September 2026 - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, announced on Monday its...